The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence

Journal of Addictive Diseases

Volumn 28, Issue 2, 2009, Pages 137-144

  Walters, David ^a   Connor, Jason P ^b,c   Feeney, Gerald F X ^b   Young, Ross McD ^b,d  

^a Private Practice   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Alcohol treatment; CBT; Cost effectiveness; Naltrexone

Indexed keywords

NALTREXONE; NARCOTIC ANTAGONIST;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ARTICLE; BEHAVIOR THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG DEPENDENCE TREATMENT; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME; AGED; ANALYSIS OF VARIANCE; AUSTRALIA; ECONOMICS; EVALUATION; HOSPITAL; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR;

ADULT; AGED; ALCOHOLISM; ANALYSIS OF VARIANCE; AUSTRALIA; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; FEMALE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; QUALITY-ADJUSTED LIFE YEARS; SUBSTANCE ABUSE TREATMENT CENTERS; YOUNG ADULT;

EID: 67651056409     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550880902772456     Document Type: Article

References (42)

1. Collins DJ Lapsley HM. Counting the cost: estimates of the social costs of drug abuse in Australia in 1998-9 Commonwealth Department of Health and Ageing Canberra 2003.
2. National Expert Advisory Committee on Alcohol 2001 National Alcohol Strategy: a plan for action 2001 to 2003-2004 Commonwealth Department of Health and Aged Care Canberra 2004.
3. Miller W Brown J Simpson T Handmaker N Bien T Luckie L Montgomery H Hester R Tonigan J. What works? A methodological analysis of the alcohol treatment and outcome literature. In: Hester R Miller W eds. Handbook of alcoholism treatment approaches: effective alternatives 2nd ed. Boston: Allyn & Bacon 1995:12-44.
4. Morgenstern J Longabaugh R. Cognitivebehavioral therapy for alcohol dependence: a review of evidence for its hypothesizedmechanism of action. Addiction. 2000;97:1475-1490
5. Project MATCH Research Group. Project MATCH secondary a priori hypotheses. Addiction. 1997;92:1671-1698
6. Kiefer F Jahn H Tarnaske T Helwig H Briken P Holzbach R et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism. Arch Gen Psychiatry. 2003; 60:92-99
7. Feeney GFX Connor JP Young RMcD Tucker J McPherson A. Combined acamprosate and naltrexone with Cognitive Behavioural Therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol. 2006; 41:321-327
8. Sindelar JL Jofre-Bonet M French MT McLellan AT. Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes. Drug Alcohol Depend. 2004;73:41-50.
9. French MT Salome HIJ Sindelar JL McLellan AT. Benefit cost analysis of addiction treatment: Methodological guidelines and applications using the DATCAP and ASI. Health Serv Res. 2002;37:433-455
10. Cartwright WS. Cost-benefit and cost-effectiveness analysis of drug abuse treatment services. Eval Rev. 1998; 22:609-636
11. Cartwright WS. Cost-benefit and cost-effectiveness analysis of drug treatment services: Reviewof the literature. Ment Health Policy Econ. 2000;3:11-26.
12. Tella MN Feinglass J Chang RW. Cost-effectiveness cost-utility and cost-benefit studies in rheumatology: a review of the literature 2001-2002. Curr Opin Rheumatol. 2003;15:27-131.
13. Cisler R Holder HD Longabaugh R Stout RL Zweben A. Actual and estimated replication costs for alcohol treatment modalities: case study from Project MATCH. J Stud Alcohol. 1998; 59:503-512
14. Holder H Longabaugh R Miller WR Rubonis AV. The cost effectiveness of treatment for alcoholism: a first approximation. J Stud Alcohol. 1991;52:517-540
15. French MT. Economic evaluation of alcohol treatment services. Eval Program Plann. 2000;23:27-29
16. French MT Dunlap LJ Zarkin GA McGeary KA McLellan AT. A structured instrument for estimating the economic cost of drug abuse treatment: The Drug Abuse Treatment Cost Analysis Program (DATCAP). J Subst Abuse Treat. 1997;14:445-455
17. Salome HJ FrenchMT Scott C FossM DennisM. Investigating the cost and benefits of addiction treatment: econometric analysis of the Chicago target Cities Project. Eval Program Plann. 2003;26:325-338
18. Connor JP Saunders JB Feeney GFX. Quality of Life in Addiction. In: Katschnig H Freeman H Sartorius N eds. Quality of life in mental disorders. New York: John Wiley & Sons Inc. 2006:199-208.
19. Gold MR Russell LB Siegel J Weinsteion MC. Cost-effectiveness in health and medicine. New York: Oxford University Press 1996.
20. Weinstein MC Siegel JE Gold MR Kamlet MS Russell LB. Recommendations of the panel on costeffectiveness in health and medicine. JAMA. 1996; 16:1253-1258
21. Neumann PJ Goldie SJWeinsteinMC. Preferencebased measures in economic evaluation in health care. Annu Rev Public Health 2000;21:587-611.
22. Deverill M Brazier J Green C Booth A. The use of QALY and Non-QALY measures of health-related quality of life: assessing the state of the art. Pharmacoeconomics 1998;13:411-420.
23. Robinson R. Cost-utility analysis. BMJ. 1993; 307:859-862
24. Brazier J Usherwood T Harper R Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol. 1998; 51:1115-1128
25. Brazier J Roberts J Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002; 271-292.
26. Ware JE Snow KK Kosinski MK Gandek B. SF- 36 health survey: manual and interpretation guide. Boston: Health Institute New England Medical Centre 1993.
27. Feeney GFX Connor JP Young RM Tucker J McPhersonA.Alcohol dependence: the impact of cognitive behaviour therapy with or without naltrexone on subjective health status. Aust N Z J Psychiatry 2004;38:842-848
28. Doran CM Fawcett J Shakeshaft A Shanahan M Mattick RP. New pharmacotherapies for alcohol dependence: are they being used and how what do they cost? Med J Aust. 2003; 179:218.
29. Pokorny AD Miller BA Kaplan HB. The Brief MAST: a shortened version of the Michigan Alcoholism Screening Test. Am J Psychiatry. 1972;129:342-344
30. Connor JP Grier M Feeney GFX Young RMcD. The validity of the Brief Michigan Alcohol Screening Test (bMAST) as a problem drinking severity measure. J Stud Alcohol Drugs. 2007;68:771-779
31. DonovanDM Kadden RM DiClemente CC Carroll KM.Client satisfactionwith three therapies in the treatment of alcohol dependence: results from project MATCH. Am J Ad. 2002;11:291-307.
32. Bandura A. Self-efficacy: the exercise of control. New York: Freeman 1997.
33. Bouza C AngelesMMunoz A Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004; 99:811-828
34. Feeney GFX Young RMcD Connor JP Tucker J McPherson A. Outpatient cognitive behavioural therapy (CBT) program for alcohol dependence: impact of Naltrexone use on outcome.AustNZ J Psychiatry. 2001;35:443-448
35. Sobell LC Sobell MB. Alcohol timeline followback (TLFB) users manual. Toronto: Addiction Research Foundation 1996.
36. Koch H Meerkerk G Zaat JOM HamMF Scholten RJPM Assendelft WJJ. Accuracy of carbohydratedeficient transferrin in the detection of excessive alcohol consumption: a systematic review. Alcohol. 2004;39:75-85.
37. Böhmer S Kohlmann T Brazier J. Sensitivity to change of the SF-3D in patients with osteoarthritis of hip or knee. Qual Life Res. 2002;11: 662.
38. Longworth L Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ. 2003;12:1061-1067
39. Streeton C Whelan G. Naltrexone a relapse prevention maintenance treatment of alcohol dependence: a metaanalysis of randomized controlled trials. Alcohol. 2001; 36:544-552
40. Briggs AH O'Brien BJ. The death of costminimization analysis? Health Economics. 2001;10:179-184
41. Feeney GFX Connor JP Young RMcD Tucker J Czajkowski F. Adherence with Naltrexone prescription advice in hospital outpatient alcohol rehabilitation program. J Clin Pharm Ther. 2001;26:73-79
42. Anton RF Moak DH Waid LR Latham PK Malcolm RJ Dias JK.Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156:1758-1764